Proteome Sciences PLC PRM,INmune Bio presenting biomarker discovery data
05 Noviembre 2021 - 1:00AM
RNS Non-Regulatory
TIDMPRM
Proteome Sciences PLC
05 November 2021
Reach announcement (non-regulatory)*
5 November 2021
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Proteome Sciences and INmune Bio to present biomarker discovery
data at Clinical Trials in Alzheimer's Disease 2021, Boston
November 5(th) 2021 - London, UK & Boca Raton, USA -
Proteome Sciences announces that Dr. Ian Pike, Chief Scientific
Officer of Proteome Sciences, will be presenting data from a recent
study performed with INmune Bio of Boca Raton, Florida, at the 2021
edition of Clinical Trials in Alzheimer's Disease conference being
held in Boston, USA from November 7(th) to 9(th) . In this study,
Proteome Sciences used its patented TMTcalibrator(TM) workflow to
discover biomarkers supporting the response of Alzheimer's disease
patients enrolled in a Phase I clinical study of INmune Bio's
XPro1595.
Xpro1595 is a novel sTNF antagonist targeting inflammation and
related processes associated with Alzheimer's disease and other
neurodegenerative conditions. A recently completed Phase I trial
showed promising results, including evidence of reduced
inflammation and re-myelination in brain white matter obtained
through imaging studies. To further support decisions for future
clinical studies, INmune Bio contracted Proteome Sciences to
deliver an in-depth proteomics analysis of cerebrospinal fluid
samples.
This analysis discovered multiple peripheral biomarkers
consistent with anti-inflammatory action, as well as pathways
related to neurodegeneration, neuronal organization, synaptic
function and myelination. Most strikingly, it revealed a broad
reduction in the phosphorylation of tau protein, which is a common
hallmark of Alzheimer's disease, and in particular at the pT217
site which has recently been reported as an important biomarker
with strongly increased levels seen in advanced disease. Several of
these proteins may be developed for monitoring progression in Phase
II clinical studies.
Dr. RJ Tesi, CEO, INmune Bio commented "The use of biomarkers to
drive clinical development forward in CNS diseases including
Alzheimer's disease may be a key to success. The use of Proteome
Science's TMTcalibrator(TM) in CSF of patients treated with XPro
has given us new insights into Alzheimer's disease and the effects
of XPro therapy."
Dr. Ian Pike said "We are delighted that INmune Bio has joined
the growing list of customers recognizing the value of our
TMTcalibrator(TM) workflow. The novel combination of diseased
tissue with peripheral fluids provides a much deeper and more
relevant mapping of biomarkers with utility for strengthening
analysis of clinical trial data. We are notably able to profile
changes in tau phosphorylation at over 30 sites with very high
sensitivity to changes, whilst also covering expression of over
3,500 other proteins. In the short-term, proteomics data can help
guide selection of dose and treatment regime for future studies,
whilst also providing more readily implemented biomarkers.
Longer-term, these biomarkers can be developed for use in the
routine clinical management of Alzheimer's disease patients."
End.
For further information:
Proteome Sciences plc
Dr Mariola Soehngen Chief Executive
Officer Tel: +44 (0)20 7043 2116
Dr Ian Pike, & Chief Scientific Officer
Allenby Capital Limited (AIM Nominated Adviser & Broker)
John Depasquale / Jeremy Porter Tel: +44 (0) 20 3328 5656
About Proteome Sciences plc. ( www.proteomics.com )
Proteome Sciences plc is a specialist provider of contract
proteomics services to enable drug discovery, development and
biomarker identification, and employs proprietary workflows for the
optimum analysis of tissues, cells and body fluids. SysQuant(R) and
TMT(R)MS2 are unbiased methods for identifying and contextualising
new targets and defining mechanisms of biological activity, while
analysis using Super-Depletion and TMTcalibrator(TM) provides
access to over 8,500 circulating plasma proteins for the discovery
of disease-related biomarkers. Targeted assay development using
mass spectrometry delivers high sensitivity, interference-free
biomarker analyses in situations where standard ELISA assays are
not available.
The Company has its headquarters in London, UK, with laboratory
facilities in Frankfurt, Germany.
*About Reach announcements
This is a Reach announcement. Reach is an investor communication
service aimed at assisting listed and unlisted (including AIM
quoted) companies to distribute media only / non-regulatory news
releases into the public domain. Information required to be
notified under the AIM Rules for Companies, Market Abuse Regulation
or other regulation would be disseminated as a regulatory
announcement via RNS and not on Reach.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRADZMGMLDVGMZM
(END) Dow Jones Newswires
November 05, 2021 03:00 ET (07:00 GMT)
Proteome Sciences (LSE:PRM)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Proteome Sciences (LSE:PRM)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024